A Prospective Study to Assess the Pediatric Respiratory Syncytial Virus (RSV) Electronic Severity and Outcome Rating System (PRESORS) and Clinical Endpoints in Neonates, Infants, and Children ?36 Months of Age Hospitalized with RSV Infection

Service: Trial Number:
Principal Investigator: Conducted at:
Miller Children's & Women's Hospital Long Beach
Currently enrolling additional patients:
Age Range:
up to 36 Months
Male & Female

The purpose of this study is to determine in hospitalized infants and children who are infected with respiratory syncytial virus (RSV) the dose-response relationship of multiple regimens of lumicitabine on antiviral activity based on nasal RSV shedding using quantitative real-time reverse transcriptase polymerase chain reaction (qRT-PCR).

MemorialCare Research Center Contact Form

For further information about this study or to express your interest in this study, please fill out and submit this form.
The email to associate with this registration.